FDA Considered A Broader Indication For Dendreon's Provenge
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The original indication proposed in the Provenge BLA was "for the treatment of men with metastatic castrate resistant (hormone refractory) prostate cancer."